Drug Name:Anifrolumab
Drug Class:Monoclonal antibody
Mechanism of Action:Blocks the activity of type I interferons, which are involved in the inflammatory process in systemic lupus erythematosus (SLE)
Use:Treatment of moderate to severe systemic lupus erythematosus (SLE) in adults who are receiving standard therapy
Side Effects:
  • Upper respiratory tract infections
  • Herpes zoster
  • Bronchitis
  • Cough
  • Headache
Contraindications:Hypersensitivity to anifrolumab or any component of the formulation
Specialty:
  • Rheumatology
  • Immunology